Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Lymphoma recurrence 5 years or later following diffuse large B-cell lymphoma: clinical characteristics and outcome.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology - 20 Apr 2010

Larouche Jean-François, Berger Françoise, Chassagne-Clément Catherine, Ffrench Martine, Callet-Bauchu Evelyne, Sebban Catherine, Ghesquières Hervé, Broussais-Guillaumot Florence, Salles Gilles, Coiffier Bertrand

Abstract excerpt

PURPOSE Patients with diffuse large B-cell lymphoma (DLBCL) usually relapse early following diagnosis but some relapses happen at 5 years or later. Few data exist regarding clinical characteristics and outcome of these patients. PATIENTS AND METHODS We performed a retrospective analysis of all patients from two centers in Lyon, France, between 1985 and 2003 who had a biopsy-proven relapse 5 years or later...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Disease-Free Survival
Share to France

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Kaplan-Meier Estimate

Share to Lymphoma, Large B-Cell, Diffuse

Share to Radiotherapy, Adjuvant

Share to Salvage Therapy

Share to Stem Cell Transplantation

Share to Transplantation, Autologous

Source

Identifiers

PMID: 20308668
DOI: 10.1200/JCO.2009.24.5860

Genes

EFS

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 5 Sept 2026. Manifest publication-graph-cohort-2026-09-05.1.

Source receipt: pubmed, retrieved 5 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Lymphoma recurrence 5 years or later following diffuse large B-cell lymphoma: clinical characteristics and outcome.PMID 20308668Read ↗

Very late relapse in diffuse large B-cell lymphoma represents clonally related disease and is marked by germinal center cell featuresSemantic proximity Read ↗

Detection of second primary lymphoma in late diffuse large B-cell lymphoma recurrencesSemantic proximity Read ↗

Extranodal Diffuse Large B Cell Lymphoma: Molecular Features, Prognosis, and Risk of Central Nervous System Recurrence.Semantic proximity Read ↗

Sudden Isolated Diffuse Large B-cell Lymphoma Transformation in Splenic Marginal Zone Lymphoma after Complete RemissionSemantic proximity Read ↗

Relapse timing is associated with distinct evolutionary dynamics in DLBCLSemantic proximity Read ↗

Large B-cell Lymphomas of Immune-Privileged Sites Relapse via Parallel Clonal Evolution from a Common Progenitor B Cell.Semantic proximity Read ↗

De novo CD5+ diffuse large B-cell lymphoma: results of a detailed clinicopathological review in 120 patients.Semantic proximity Read ↗

Genetic background and evolution of relapses in aggressive B-cell lymphomas.Semantic proximity Read ↗

Clonal evolution in diffuse large B-cell lymphoma with central nervous system recurrenceSemantic proximity Read ↗

Clonal Evolution in Primary Diffuse Large B-Cell Lymphoma of the Central Nervous System.Semantic proximity Read ↗

Aberrant bcl6 protein expression in patients with EMZL following recurrence or progression: case report of two casesSemantic proximity Read ↗

Consolidative breast radiotherapy and prophylactic high-dose methotrexate are important first-line treatments for primary breast diffuse large B-cell lymphoma patients treated with R-CHOP-like regimensSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.